Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Takashi TanakaTakahiro Fukuda

Abstract

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell transplantation (HCT). Eltrombopag is an oral thrombopoietin receptor agonist whose efficacy against persistent thrombocytopenia after allogeneic HCT has not been well characterized. This retrospective study evaluated the safety and efficacy of eltrombopag in 12 consecutive patients with persistent thrombocytopenia after allogeneic HCT. Eltrombopag was started at 12.5 mg once daily and the dose was increased by 12.5 mg daily every week until platelet counts exceeded 50,000/μL. Five patients had prolonged isolated thrombocytopenia (PIT) and 7 patients had secondary failure of platelet recovery (SFPR). The cumulative incidence rate of successful platelet recovery to ≥50,000/μL without transfusion support was 60% in PIT patients and 71% in SFPR patients. No patients discontinued the drug because of adverse events or intolerability. Notably, the rate of platelet recovery was higher (100% versus 58%; P = .0017) and recovery was faster (median, 33 days versus 137 days; P = .0078) in patients with normal numbers of bone marrow megakaryocytes before starting eltrombopag than in those with decreased numbers of megakaryocytes. Eltrombopag is a promis...Continue Reading

References

Apr 17, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·B BrunoR A Nash
Feb 10, 2007·Blood·David J Kuter
Feb 18, 2011·American Journal of Hematology·Daan DierickxDrew Provan
Sep 20, 2011·Bone Marrow Transplantation·C CalmettesN Milpied
May 11, 2012·American Journal of Hematology·Robin ReidJane Liesveld
Jul 6, 2012·The New England Journal of Medicine·Matthew J OlnesCynthia E Dunbar
Aug 11, 2012·Lancet·Neil BlumbergRichard P Phipps
Aug 24, 2012·The New England Journal of Medicine·Nezam H AfdhalUNKNOWN ELEVATE Study Group
Jan 8, 2013·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·David L DeRemerFarrukh T Awan
Oct 15, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jane L LiesveldYuhchyau Chen
Jun 19, 2015·International Journal of Hematology·Natalia MaximovaR Paparazzo

❮ Previous
Next ❯

Citations

Jul 22, 2016·Transfusion Medicine Reviews·Jennifer Webb, Allistair Abraham
Oct 26, 2018·Bone Marrow Transplantation·D RiveraJ R Gonzalez-Porras
Jun 18, 2019·Journal of Pediatric Hematology/oncology·Jowita FrączkiewiczMarek Ussowicz
Aug 30, 2019·Bone Marrow Transplantation·Zachariah DeFilippDavid J Kuter
Aug 5, 2020·Expert Review of Hematology·Mi KwonJosé Luis Díez-Martín
May 20, 2020·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Ram Vasudevan Nampoothiri, Rajat Kumar
Jan 27, 2019·Bone Marrow Transplantation·Serena MarottaAntonio M Risitano
Feb 18, 2020·Pediatric Blood & Cancer·Riccardo MasettiFranco Locatelli
Nov 17, 2020·Therapeutic Advances in Hematology·Semra AydinAlessandro Busca
Dec 13, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Upendra MahatRabi Hanna
Mar 21, 2021·Pediatric Transplantation·M Luz Uria-OficialdeguiCristina Diaz-de-Heredia
Apr 4, 2021·Journal of Clinical Medicine·Avi LeaderGalia Spectre
Apr 1, 2021·Transplantation and Cellular Therapy·Georgios E ChristakopoulosAngela R Smith
Apr 21, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fei-Fei TangXiao-Jun Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.